180 related articles for article (PubMed ID: 32203137)
1. Leukemia-induced dysfunctional TIM-3
Blaeschke F; Willier S; Stenger D; Lepenies M; Horstmann MA; Escherich G; Zimmermann M; Rojas Ringeling F; Canzar S; Kaeuferle T; Rohlfs M; Binder V; Klein C; Feuchtinger T
Leukemia; 2020 Oct; 34(10):2607-2620. PubMed ID: 32203137
[TBL] [Abstract][Full Text] [Related]
2. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Clin Immunol; 2018 May; 190():32-40. PubMed ID: 29477343
[TBL] [Abstract][Full Text] [Related]
3. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Dama P; Tang M; Fulton N; Kline J; Liu H
J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia.
Mikami T; Kato I; Wing JB; Ueno H; Tasaka K; Tanaka K; Kubota H; Saida S; Umeda K; Hiramatsu H; Isobe T; Hiwatari M; Okada A; Chiba K; Shiraishi Y; Tanaka H; Miyano S; Arakawa Y; Oshima K; Koh K; Adachi S; Iwaisako K; Ogawa S; Sakaguchi S; Takita J
Cancer Sci; 2022 Jan; 113(1):41-52. PubMed ID: 34716967
[TBL] [Abstract][Full Text] [Related]
6. Increased exhausted CD8
Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
[TBL] [Abstract][Full Text] [Related]
7. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C.
Osuch S; Laskus T; Berak H; Perlejewski K; Metzner KJ; Paciorek M; Radkowski M; Caraballo Cortés K
Sci Rep; 2020 Sep; 10(1):16060. PubMed ID: 32994477
[TBL] [Abstract][Full Text] [Related]
8. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
[TBL] [Abstract][Full Text] [Related]
9. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL).
Stachel D; Albert M; Meilbeck R; Kreutzer B; Haas RJ; Schmid I
Eur J Med Res; 2006 Mar; 11(3):102-13. PubMed ID: 16751110
[TBL] [Abstract][Full Text] [Related]
11. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
[TBL] [Abstract][Full Text] [Related]
12. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
[TBL] [Abstract][Full Text] [Related]
13. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
[TBL] [Abstract][Full Text] [Related]
14. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.
Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Zhu L; Zeng H; Schell TD; Zheng H
Blood Cancer J; 2015 Jul; 5(7):e330. PubMed ID: 26230954
[TBL] [Abstract][Full Text] [Related]
15. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.
Li Z; Liu X; Guo R; Wang P
Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007
[TBL] [Abstract][Full Text] [Related]
16. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
17. Splenic CD4
Huang N; Zhou R; Chen H; Zhang S; Li J; Wei W; Sun J; Ren S; Li B; Deng H; Yang J; Ji F; Li Z
Int J Immunopathol Pharmacol; 2021; 35():20587384211061051. PubMed ID: 34930041
[No Abstract] [Full Text] [Related]
18. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
20. Low expression of
Cui L; Gao C; Wang CJ; Liu SG; Wu MY; Zhang RD; Li ZG
Pediatr Hematol Oncol; 2020 Nov; 37(8):732-746. PubMed ID: 32804017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
